Fingerprint
Dive into the research topics of 'Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically